Showing 1571-1580 of 2314 results for "".
- OcuTerra Therapeutics Announces First Patient Dosed in OTT166 Phase 2 DR:EAM Clinical Trial for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-therapeutics-announces-first-patient-dosed-in-ott166-phase-2-dream-clinical-trial-for-diabetic-retinopathy/2481009/OcuTerra Therapeutics announced that the first patient was dosed in its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating OTT166 in adult patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) or mild proli
- Aerie Pharmaceuticals Announces First Patient Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-comet-3-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2481006/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-3” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-3 is the second of three trials in the p
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-davio-2-clinical-trial-of-eyp-1901-for-the-maintenance-treatment-of-wet-amd/2481005/EyePoint Pharmaceuticals, Inc., announced that the first patient has been dosed in the Phase 2 Durasert® and Vorolanib in Ophthalmology 2 (DAVIO 2) clinical trial of EYP-1901, an investigational sustained delivery antivascular endothelial growth factor (anti-VEGF) treatment for wet
- Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-completes-dosing-in-oasis-phase-12a-clinical-trial-of-cls-ax-in-wet-amd-patients/2480989/Clearside Biomedical announced today completion of dosing in Cohorts 3 and 4 of OASIS, its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a US-based, multicen
- Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Diseasehttps://modernod.com/news/nanoscope-therapeutics-announces-first-patient-dosed-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease/2480985/Nanoscope Therapeutics announced that the first patient has been dosed in a phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy for Stargardt disease. “This trial represents the second indication for our vision restoring
- Bausch + Lomb CEO Joseph C. Papa to Step Downhttps://modernod.com/news/joseph-c-papa-to-step-down-from-ceo-role-at-bausch-lomb/2480983/Bausch + Lomb announced Joseph C. Papa has stepped down as chair of the Board of Directors and plans to step down as CEO. The board appointed Thomas W. Ross, Sr., to serve as the chair, and has begun a search for a new CEO. Mr. Papa will remain as CEO and as a member of the bo
- DORC Obtains FDA 510(k) Clearance for Eva Nexus Systemhttps://modernod.com/news/dorc-obtains-fda-510k-clearance-for-eva-nexus-system/2480959/DORC International has announced 510(k) market clearance and the launch of the Eva Nexus. According to DORC, the Eva Nexus features multiple innovations to improve performance, efficiency, and stability for retina surgeons, including Smart IOP for anterior
- Dopavision Appoints Mark S. Wuttke, PhD, as Chief Executive Officerhttps://modernod.com/news/dopavision-appoints-mark-s-wuttke-phd-as-chief-executive-officer/2480881/Dopavision announced that Mark S. Wuttke, PhD, has been appointed as the company´s Chief Executive Officer. He succeeds Dopavision´s co-founder and previous Managing Director Stefan Zundel, who will remain on Dopavision´s advisory board and continue to advise the company.</
- Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 COMET-2 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-phase-3-comet-2-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2480879/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-2” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-2 is the first of three trials in t
- Life After Death for the Human Eye: Vision Scientists Revive Light-Sensing Cells in Organ Donor Eyeshttps://modernod.com/news/life-after-death-for-the-human-eye-vision-scientists-revive-light-sensing-cells-in-organ-donor-eyes/2480858/Scientists have revived light-sensing neuron cells in organ donor eyes and restored communication between them as part of a series of discoveries that stand to transform brain and vision research, accor